

A hospital antibiogram is a mirror of the situation of the pathologic organism's status in your hospital along with the area surrounding you. It will even show the situations where you are getting patients every day. So analysis of your antibiogram is very much essential and sharing it will help millions of people in your geographical area.

With this article which comprises 878 positive isolates from January 2023 to December 2023, we will have a glance at the situation currently we are in.


JAN 2023- December 2023



CULTURE POSITIVE SAMPLE SIZE = 878



A.OPD ANTI BIOGRAM



URINE INFECTIONS- OPD ANTI BIOGRAM


COMMUNITY ACQUIRED













3 cases of *Proteus* spp, 2 cases each of *Citrobacter* spp, *Elizabethkingia* spp, and *Streptococcus agalactiae*


URINE INFECTIONS - OPD ANTI BIOGRAM**HOSPITAL ACQUIRED**

1 case each of *Klebsiella* spp, *Enterococcus* spp and *Pseudomonas* spp

RESPIRATORY TRACT INFECTIONS (RTI)- OPD ANTI BIOGRAM**COMMUNITY ACQUIRED**

1 case each of Klebsiella spp, Enterococcus spp and Pseudomonas spp



4 cases of Streptococcus pneumoniae.



BLOOD INFECTIONS - OPD ANTI BIOGRAM


2 cases each of Candida spp, Elizabethkingia spp and Saphylococcus spp, 1 case each of Citrobacter spp, E.coli and Stenotrophomonas spp

URINARY TRACT INFECTIONS (UTI)- INDOOR ANTI BIOGRAM



COMMUNUR ACQUIRED












3 cases each of *Staphylococcus haemolyticus* Coagulase-negative *Staphylococcus* species and *Acinetobacter* species. 2 cases of *Staphylococcus saprophyticus* and *Citrobacter* species. 1 case each of *Serratia* species, *Providencia* species and *Sphingomonas* species.





3 cases of Enterobacter species and 2 cases of Staphylococcus haemolyticus.









3 cases of Streptococcus pneumoniae, 3 cases of Burkholderia species

RESPIRATORY TRACT INFECTIONS - INDOOR ANTI BIOPGRAM

HOSPITAL ACQUIRED








4 cases of Ecoli and 4 cases of Enterobacter spp.



BLOOD INFECTIONS - INDOOR ANTI BIOGRAM




COMMUNITY ACQUIRED







4 cases of Escherichia coli and Pseudomonas spp, 2 cases each of Enterococcus spp, Klebsiella spp and Burkholderia spp, 1 case of CONS


BLOOD INFECTIONS - INDOOR ANTI BIOTRIGRAM**HOSPITAL ACQUIRED**







SKIN/ SOFT TISSUE INFECTIONS- INDOOR ANTI BIOGRAM







4 cases of Serratia species, 3 cases of Enterococcus species, 2 cases each of Acinetobacter species and Proteus species, 1 cases each of Pseudomonas species, Enterobacter species, and Aeromonas species.

* * *

Analysis and Conclusion:

The analysis shows a clear picture of the dominance of Klebsiella followed by Acinetobacter in this part of the country. The sensitivity of these pathogens is very

scary to see. *Pseudomonas*, VRE, and MRSA are also in the line, so need to be careful. Judicious use of antibiotics, and combination therapy de-escalation in a timely manner is the need of the hour. Segregation of patients with difficult-to-treat situations can be lifesaving. Currently, Phage therapy, polymeric biomaterials, nanoparticles, and plant-derived products are being in trials but till then we need to be vigilant.

References:

1. Parmanik A, Das S, Kar B, Bose A, Dwivedi GR, Pandey MM. Current Treatment Strategies Against Multidrug-Resistant Bacteria: A Review. *Curr Microbiol*. 2022 Nov 3;79(12):388. doi: 10.1007/s00284-022-03061-7. PMID: 36329256; PMCID: PMC9633024.
2. Pal N, Sharma P, Kumawat M, Singh S, Verma V, Tiwari RR, Sarma DK, Nagpal R, Kumar M. Phage therapy: an alternative treatment modality for MDR bacterial infections. *Infect Dis (Lond)*. 2024 Jul 17:1-33. doi: 10.1080/23744235.2024.2379492. Epub ahead of print. PMID: 39017931.

Author:

1. Dr. Apurba Kumar Borah, Consultant, Critical Care Medicine
2. Dr. Vicky Lahkar, Consultant Microbiologist

Author



[CCEM Journal](#)

[View all posts](#)